The FDA gave orphan drug designation to Abeona Therapeutics' ABO-202, which is being developed as a treatment for infantile Batten disease. The company expects to launch clinical trials of the drug candidate this year.
FDA orphan status granted to Abeona's infantile Batten disease drug
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.